EUVIMEDEUVIMED entdecken
Vergleichsstudie

Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions

Laurens A van Walraven, Vitória M Kalil, Daphne van der Veen, Michel J Bosiers, Koen Deloose, Suzanne Holewijn, Clark J Zeebregts, Michel M P J Reijnen

Journal of Vascular Surgery · 2024

DOI: 10.1016/j.jvs.2024.03.449 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2024. Verfasst von Laurens A van Walraven und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands; Multi-Modality Medical Imaging Group, University of Twente, Enschede,…. Hauptthemen laut MEDLINE: Femoral Artery, Peripheral Arterial Disease, Vascular Patency, Drug-Eluting Stents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: In two randomized controlled trials, the outcomes of endovascular treatment of complex femoropopliteal arterial lesions were compared with bypass surgery and considered a valid alternative treatment. The aim of this study was to compare both endovascular treatment options with the hypothesis that implantation of heparin-bonded self-expanding covered stents (Viabahn [SECS]) or drug-eluting stents (ZilverPTX [DES]) are related to similar clinical outcomes at 1-year follow-up. METHODS: In a post-hoc analysis, the SuperB trial and Zilverpass databases were merged. Patients in the endovascular treatment arms were included, and data was analyzed in an intention-to-treat (ITT) and a per-protocol (PP) fashion. Data included baseline and lesion characteristics, procedural details, and follow-up data. The primary endpoint of this study was primary patency at 1-year follow-up. The secondary endpoints were secondary patency, target lesion revascularization (TLR), limb loss, and all-cause mortality. RESULTS: A total of 176 patients were included; 63 in the SECS arm and 113 in the DES arm. Through 1-year follow-up, there were no significant differences in primary patency (ITT: 63.4% vs 71.1%: P = .183 and PP: 60.8% vs 71.1%; P = .100). Secondary patency rates were not significantly different in the ITT analysis (86.5% vs 95.1%; P = .054), but in the PP analysis, there was a significant difference in favor of the DES group (SECS, 85.6% vs DES, 95.1%; P = .038). There was no significant difference in freedom from TLR between groups (79.6% vs 77.0%; P = .481). No major amputations were performed in the SECS group, and two were performed in the DES group (1.8%). Survival rate was 98.2% in the SECS group, and 91.3% in the DES group after 1-year follow-up (P = .106). Based on diagnosis (intermittent claudication vs chronic limb-threatening ischemia) no differences between patients with intermittent claudication and chronic limb-threatening ischemia were observed in primary patency, secondary patency and freedom from TLR. CONCLUSIONS: Treatment of complex femoropopliteal arterial disease with the heparin-bonded Viabahn endoprosthesis and the Zilver PTX drug-eluting stent are related to similar primary and secondary patency, and TLR rates at 1 year, except for secondary patency in the PP analysis. This study further supports the endovascular treatment of long complex lesions in the femoropopliteal artery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Femoral ArteryPeripheral Arterial DiseaseVascular PatencyDrug-Eluting StentsLimb SalvageEndovascular ProceduresHumansMaleFemaleAgedTime FactorsTreatment OutcomeCoated Materials, BiocompatibleHeparinMiddle AgedRisk FactorsProsthesis DesignAmputation, SurgicalAnticoagulantsAged, 80 and overDatabases, FactualStentsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Covered stentsDrug eluting stentsSFA

Substanzen

Coated Materials, BiocompatibleHeparinAnticoagulants

Autor:innen und Institutionen

  • Department of Surgery, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands; Multi-Modality Medical Imaging Group, University of Twente, Enschede, The Netherlands.
  • Albert Einstein Hospital College, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil.
  • Department of Surgery, Rijnstate, Arnhem, The Netherlands.
  • Department of Vascular Surgery, St. Franziskus-Hospital, Munster, Germany; Department of Vascular Surgery, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium.
  • Department of Surgery (Division of Vascular Surgery), University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Zitieren

APA

van Walraven, L. A., Kalil, V. M., van der Veen, D., Bosiers, M. J., Deloose, K., Holewijn, S., Zeebregts, C. J., & Reijnen, M. M. P. J. (2024). Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2024.03.449

Vancouver

van Walraven LA, Kalil VM, van der Veen D, Bosiers MJ, Deloose K, Holewijn S, et al. Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions. Journal of Vascular Surgery. 2024. doi:10.1016/j.jvs.2024.03.449

BibTeX
@article{vanWalraven2024,
  author = {van Walraven, Laurens A and Kalil, Vitória M and van der Veen, Daphne and Bosiers, Michel J and Deloose, Koen and Holewijn, Suzanne and Zeebregts, Clark J and Reijnen, Michel M P J},
  title = {Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions},
  journal = {Journal of Vascular Surgery},
  year = {2024},
  doi = {10.1016/j.jvs.2024.03.449}
}
Kostenlos starten →